Logo Università degli Studi di Milano



moglynet, phd programma, marie curie action, itn



Scholarship Programme Promoting Institutional Cooperation and Mobility for 12 early stage researchers


The mission of MoGlyNet is to define a joint doctorate educational training model in Drug Discovery and Development where Academia and Industry, supported by other institutions/organizations, join their forces for:

  • Creating a common platform of knowledge and language for 12 early stage researchers(ESR) working in the Drug Discovery and Development area aiming to convey complementary Pharma-skills
  • Exploiting this platform to train a new generation of cutting-edge researchers and professionals highly attractive for employment by the European Pharma-industry and regulatory authorities
  • Establishing structures for long-term cooperation, strengthening the relationships among the leading Universities and Pharma-enterprises and to continuously develop the research training platform that European industry relies on

Doctorate Courses/Schools

  • University of Milan: Pharmaceutical Sciences
  • University of Milan: Experimental and Clinical Pharmacological Sciences
  • University of Aberdeen: Graduate School in Life Sciences and Medicine
  • University of Antwerp: Antwerp Doctoral School
  • University of Barcelona Doctoral School
  • University of Leiden: Graduate School of Leiden University Medical Center

Research project

Atherosclerotic cardiovascular disease is the major cause of death in the western world. Thanks to cholesterol-lowering drugs, the lifespan and wellbeing of patients have been significantly improved. However, a large group of patients does not fully benefit from current lipid-lowering strategies.
Our multidisciplinary approach is focused on counteracting neovessel formation to prevent plaque rupture and its cardiovascular complications, thus leading to a more effective therapy for atherosclerosis.

Research methodology and approach

The MoGlyNet consortium is strongly multidisciplinary and takes advantage of a number of different state-of-the-art technologies and methodologies:

  • Computational chemistry and synthesis
  • Bioanalytics and biophysics
  • In vitro and in vivobiological evaluation
  • Imaging
  • Metabolomic and Proteomic studies
  • Oxidative stress studies


  • University of Milan (Pharmaceutical Sciences and Pharmacological and Biomolecular Sciences Departments), Italy – Coordinating University
  • University of Aberdeen (Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition), UK
  • University of Antwerp (Laboratory of Physiopharmacology), Belgium
  • University of Barcelona (Department of Biochemistry and Molecular Biology), Spain
  • Leiden University Medical Center (Department of Surgery and Einthoven Laboratory for Experimental Vascular Medicine), The Netherlands

Partners and Associations

  • Bayer HealthCare Manufacturing S.r.l., Italy
  • Biomax Informatics AG, Germany
  • HistoGeneX N.V., Belgium
  • KemoTech Srl, Italy
  • Linkcare Health Services, Spain
  • Ingenus Pharmaceutical GmbH, Switzerland
  • PPD Italy srl, Italy
  • EIPG (European Industrial Pharmacists Group)
  • EAS (European Atherosclerosis Society)
  • EDQM (European Directorate for the Quality of Medicines

Tel. +390250314471
Fax +390250314476



This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 67552

01 settembre 2015
Torna ad inizio pagina